ABLD — AbL Diagnostics SA Share Price
Last trade - 00:00- €51.24m
- €52.71m
- €8.75m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.64 | ||
| Price to Tang. Book | 7.83 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.58 | ||
| EV to EBITDA | 115.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.96% | ||
| Return on Equity | 26.12% | ||
| Operating Margin | 1.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0.34 | n/a | n/a | n/a | 8.75 | n/a | n/a | 67.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -75.44 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ABL Diagnostics SA, formerly known as Etablissements Fauvet Girel SA is a France-based company which provides container leasing for rail freight and management of holdings in companies in this sector of activity. The Company also provides Commercial and Industrial Machinery and Equipment Rental and Leasing services.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 1st, 1981
- Public Since
- March 25th, 1991
- No. of Employees
- 19
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 16,113,904
- Address
- 40 boulevard Henri Sellie, SURESNES, 92150
- Web
- https://www.abldiagnostics.com/
- Phone
- +33 145061574
- Auditors
- Ficorec Audit
Upcoming Events for ABLD
Similar to ABLD
Affluent Medical SAS
Euronext - Paris
Alpha MOS SA
Euronext - Paris
Amplitude Surgical SA
Euronext - Paris
Biomerieux SA
Euronext - Paris
Biosynex SA
Euronext - Paris
FAQ
As of Today at 19:00 UTC, shares in AbL Diagnostics SA are trading at €3.18. This share price information is delayed by 15 minutes.
Shares in AbL Diagnostics SA last closed at €3.18 and the price had moved by -63.45% over the past 365 days. In terms of relative price strength the AbL Diagnostics SA share price has underperformed the FTSE Global All Cap Index by -65.68% over the past year.
There is no consensus recommendation for this security.
AbL Diagnostics SA does not currently pay a dividend.
AbL Diagnostics SA does not currently pay a dividend.
AbL Diagnostics SA does not currently pay a dividend.
To buy shares in AbL Diagnostics SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €3.18, shares in AbL Diagnostics SA had a market capitalisation of €51.24m.
Here are the trading details for AbL Diagnostics SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ABLD
Based on an overall assessment of its quality, value and momentum AbL Diagnostics SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AbL Diagnostics SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -71.48%.
As of the last closing price of €3.18, shares in AbL Diagnostics SA were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The AbL Diagnostics SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €3.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
AbL Diagnostics SA's management team is headed by:
- Gilles Dambrine - CHM
- Bruno Dambrine - DRC
- Stephane Prefol - DRC